Global Hepatitis B Infection Treatment Market Report and Forecast 2025-2034

Global Hepatitis B Infection Treatment Market

The hepatitis B infection treatment market size attained a value of about USD 4.5 billion in 2024, driven by the rising cases of hepatitis infections and better diagnostic procedures. The market is further expected to grow at a CAGR of 3.6% during the forecast period of 2025-2034 to reach a value of nearly USD 6.1 billion by 2034.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Hepatitis B Infection Insights: Types, Causes, Diagnosis, and Treatment

Hepatitis B infection is a serious hepatic disorder caused by the Hepatitis B Virus (HBV). Hepatitis B infection is of two types, acute and chronic. The acute hepatitis B infection lasts for less than six months, while the chronic one lasts for more than six months to years.

The symptoms of hepatitis B infection depend on the age, sex, and clinical profile of the patient. The symptoms may vary from moderate to severe and include abdominal pain, joint pain, nausea and vomiting, dark urine, high fever, pale skin, weakness, and fatigue.

The main cause of the hepatitis B infection is the hepatitis B virus, which can be transmitted into the healthy body through sneezing, sexual contact, sharing of needles or any other products with the infected person. The virus can also be transmitted from infected pregnant women to their neonates.

Hepatitis B infection is diagnosed with the help of blood tests, liver ultrasound, and liver biopsy. Blood tests help in the detection of the infection and confirm whether it is acute or chronic. Ultrasound and liver biopsy help to analyse the liver damage.

The treatment of hepatitis B infection includes antiviral medications, interferon injection, and liver transplant. These medications help in the slower progression of the hepatitis B infection and thus prevent further damage to the hepatic system. Newborns and children under the age of 5 are at a higher risk of chronic hepatitis B infection.  

According to this study, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Indication Type

• Acute

• Chronic

Market Breakup by Treatment Type

• Antiviral Drugs
  • Tenofovir Disoproxil
  • Entecavir 
  • Telbivudine 
  • Lamivudine 
  • Others
• Vaccines
• Immune Modulator Drugs
  • Pegylated Interferon
  • Interferon Alpha
• Surgery
• Others

Market Breakup by Diagnosis Type

• Hepatitis B Enzyme Immuno Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests

• Hepatitis B Nucleic Acid Amplification Tests (NAATs)

• Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Hepatitis B Infection Treatment Market Scenario

The hepatitis B infection treatment market is primarily driven by the rising cases of hepatitis B infection in developed and developing nations. According to the World Health Organisation, in 2015, around 257 patients are infected with hepatitis B infection globally. The disease burden is expected to increase in the upcoming years, which has led to increased demands for therapeutics, thus attributing to the market growth.

The hepatitis B infection treatment market is further driven by raising awareness about the disease, its pathogenesis, awareness, and treatment. Several initiatives are implemented by the government and non-government organisations to raise awareness about the transmission and preventative measures of the disease. This is anticipated to augment the market growth during the forecast period.

With the increasing patient pool, major pharmaceutical companies are working on the invention of novel and more effective therapeutic methods that are expected to bolster the hepatitis B infection treatment market development.

Other factors such as technological advancements, increased investments, better screening procedures, and novel product launches and approvals are expected to drive the hepatitis B infection treatment market growth forward in the coming years.

Regional Outlook: North America and Asia Pacific Account for Significant Shares

North America is anticipated to hold a significant share of the hepatitis B infection treatment market owing to the presence of strategic key players, advanced healthcare infrastructure, and increased adoption of improved palliative care.

The Asia Pacific region is expected to witness the fastest market growth during the forecasted period due to the rapidly developing medical diagnostic sector, favouring government initiatives, and increasing disposable incomes and economies.

Therapeutic Landscape

The treatment of hepatitis B infection is based on the symptoms and severity of the disease. In the case of acute conditions, there is no need for any proper management technique, while in the case of chronic hepatitis, the healthcare provider prescribes several medications and treatment procedures to manage the further progression of the disease.

Standard Available Therapeutic Options

The standard line treatment for hepatitis B is the administration of antiviral medications, that act against the virus and thus slow down liver damage. The most used antiviral drugs are Tenofovir, Telbivudine, Entecavir, Adefovir, and Lamivudine.

Artificial or man-made versions of natural substances produced by the body are also used for the treatment of hepatitis B. These include interferon alpha-2b for providing long-term disease treatment. These drugs also aid in the prevention of cirrhosis, reduce the risk of liver cancer, and increase long-term survival.

Surgical interventions are being implemented in case of medication intolerant patients or medication failure. A liver transplant is a surgical therapeutic intervention used to eliminate the damaged liver and replaced it with a healthy one. 

Other than the available treatment options, secondary care is aimed at ensuring comfort, maintaining a balanced nutritional portfolio, and improving the quality of living. 

Clinical Trials Landscape

The treatment for hepatitis B is primarily aimed at providing a functional cure. This refers to the reduction in the disease markers and virus responsible for causing the disease. The currently available therapeutic strategies do suppress the viral DNA levels but fail to provide a functional cure. This brings in the need for the development of novel medicines that act against the several cycles of the chronic hepatitis B virus.

At present, there are more than thirty new HIV medications that are under clinical development and trials. The discovery of novel therapeutic agents has grabbed the attention of investors and is anticipated to stimulate the hepatitis B infection treatment market during the forecast period.

Undergoing Clinical Trials and Emerging Drug Therapies

In 2021, Assembly Biosciences and Antios Therapeutics clinically collaborated for the discovery of combination therapy using the three different drug categories. The trial is evaluating the tenofovir disproxil fumarate, ATI 2173, and AB-279 in patients suffering from chronic hepatitis B infections. 

Assembly, a key market player, has teamed up with Arbutus Biopharma for testing a dual combination therapy of AB-729 with Verbicorvir. The monotherapeutic trial is also being conducted by the former for investigating ABI-H3733, a core inhibitor in the treatment of hepatitis B infection.

VBI Vaccines and Bril Biosciences are conducting Phase II clinical trials for the new recombinant protein-based immunotherapeutic drug candidate for chronic hepatitis B infection. The drug has shown some promising effects in trials and has induced both T-cell and B-cell responses.

Arbutus Biopharma Corporation is also conducting Phase II trials for the novel investigational therapy, AB-729. The drug is under clinical studies for assessing its efficacy, tolerability, and adverse effects, alone and in combination. 

The discovery of these novel therapeutic interventions will assist in the proper diagnosis and treatment of hepatitis B infection. The novel product launches will facilitate the expansion of the market.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the hepatitis B infection treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Accord Healthcare (Intas Pharmaceuticals Ltd.)

• Apotex Inc. (SK Capital Partners)

• Arbutus Biopharma

• Arrowhead Pharmaceuticals, Inc.

• Aurobindo Pharma

• Bristol-Myers Squibb Company

• Gilead Sciences, Inc.

• GSK plc

• Lupin

• Merck & Co., Inc.

• Par Pharmaceutical (Endo International plc)

• Teva Pharmaceutical Industries Ltd.

• Zydus Healthcare Limited

Key Highlights of the Report